DEVICE · Unmapped registry intervention
Endogenex Treatment
Find medicine records ·
Find other trials using this name
Clinical trial
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
NCT06267391
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DEVICE · Unmapped registry intervention
Sham Procedure
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedSafety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: NA
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Type2diabetesunresolved
Diabetesverified · MONDO: diabetes mellitus
Interventions
Endogenex TreatmentDEVICE
Sham ProcedureDEVICE
Sponsors & collaborators
Endogenex, Inc.lead sponsor
Mapped research locations
DallasTexas, United States3AustinTexas, United States3HoustonTexas, United States2Los AngelesCalifornia, United States2MiamiFlorida, United States2San AntonioTexas, United States2BirminghamAlabama, United States2OrlandoFlorida, United States2BaltimoreMaryland, United States1ColumbusOhio, United States1JacksonvilleFlorida, United States1RochesterMinnesota, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06267391 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.